


MK-0966 Prot. No. 072
Phase III Postorthopedic Surgical Pain

APPENDIX 4.1

Appendix 4.1.37: Five-Page Summary of Efficacy (Cont.)

Analysis of PRID over Time (Intention-to-Treat)



Treatment		Summary Statistics by Timepoint (Hours Postdose, Last Value Carried Forward)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N †	53	53	45	33	27	21	16	8	8	7	2
	MEAN	1.0 A	1.3 B	1.4 B	1.3 B	1.3 B	0.9 B	0.8 B	0.8 B	0.8 B	0.6 B	0.7 B
	STD	1.5	1.9	2.1	2.0	2.0	1.7	1.8	1.6	1.8	1.5	1.7
MK-0966 80 mg	N †	110	110	97	86	80	48	58	52	46	46	40
	MEAN	1.2 A	2.1 A	2.5 A	2.6 A	2.5 A	2.5 A	2.6 A	2.6 A	2.4 A	2.4 A	2.2 A
	STD	1.4	1.7	1.9	2.3	2.3	2.6	2.6	2.6	2.5	2.5	2.4
Naproxen Sodium	N †	55	55	52	49	44	32	28	27	21	19	14
	MEAN	1.0 A	2.4 A	2.7 A	2.6 A	2.4 A	2.2 A	2.3 A	2.0 A	2.1 A	2.0 A	2.0 A
	STD	1.5	1.6	1.9	2.1	2.3	2.4	2.5	2.3	2.3	2.3	2.3
Pooled SD		1.4	1.7	1.9	2.2	2.2	2.3	2.3	2.3	2.2	2.2	2.2
Effect		p-Values by Timepoint (Hours Postdose)										
Treatment ††		0.741	0.004	0.001	0.002	0.007	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Baseline Pain Intensity (PI) ††		0.997	0.654	0.864	0.539	0.981	0.761	0.953	0.770	0.574	0.776	0.805
Center (Study Site) ††		<0.001	0.065	0.291	0.191	0.032	0.006	0.035	0.070	0.056	0.069	0.021
Surgical Procedure (Surgery) ††		0.195	0.472	0.201	0.748	0.126	0.033	0.064	0.073	0.098	0.067	0.174
Rx-by-Baseline PI Interaction †††		0.842	0.663	0.397	0.757	0.261	0.798	0.787	0.996	0.997	0.939	0.985
Rx-by-Center Interaction †††		0.266	0.480	0.081	0.795	0.328	0.439	0.271	0.708	0.765	0.646	0.797
Rx-by-Surgery Interaction †††		0.174	0.987	0.492	0.189	0.078	0.327	0.301	0.324	0.191	0.566	0.635


†: Observed sample size
 ††: Model included baseline Pain Intensity (PI), center, surgical procedure, and treatment as factors.
 †††: Model included baseline PI, center, surgical procedure, treatment, and the three factor-by-treatment interactions.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level. All p-values from the pairwise comparisons are provided in Appendix [4.1.3] of the CSR

MK-0966 Prot. No. 072
Phase III Postorthopedic Surgical Pain

APPENDIX 4.1

Appendix 4.1.37: Five-Page Summary of Efficacy (Cont.)

Analysis of Time to Confirmed Perceptible Pain Relief
(Stopwatch Time of Perceptible Pain)




Treatment	N	Number(% ^a) of Patients with Confirmed Perceptible Pain Relief	Time (Hour) to Confirmed Perceptible Pain Relief by Percentile		
			25th	50th (95% CI)	75th
Placebo	53	21 (39.6)	0.6	NE	NE
MK-0966 50 mg	110	64 (58.2)	0.5	0.9 (0.7, =) A	NE
Naproxen Sodium	55	29 (52.7)	0.5	1.2 (0.7, =) AB	NE
Effect					p-Value
Treatment					0.073
Baseline Pain Intensity (PI)					0.118
Surgical Procedure					0.059
Center (Study Site)					<0.001
<p>^a: Kaplan-Meier estimate of incidence rate (This may be different from the crude rate).</p> <p>A, B, C — Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.</p> <p>NE: Not estimable.</p> <p>All p-values from the pairwise comparisons are provided in Table 25 of the CSR.</p>					

MK-0966 Prot. No. 072
Phase III Postorthopedic Surgical Pain

APPENDIX 4.1


Appendix 4.1.37: Five-Page Summary of Efficacy (Cont.)
Analysis of Time to Rescue Medication Use Within 12 Hours



Treatment	N	Number(% ^o) of Patients Requiring Rescue Medication	Time (Hour) to Rescue Medication by Percentile		
			25th	50th (95% CI)	75th
Placebo	53	51 (96.2)	1.3	2.8 (1.8, 3.8) B	5.0
MK-0966 50 mg	110	72 (66.5)	2.3	5.3 (4.0, 8.1) A	NE
Naproxen Sodium	55	40 (73.6)	3.0	5.3 (3.3, 7.5) A	NE
Effect					p-Value
Treatment					<0.001
Baseline Pain Intensity (PD)					0.003
Surgical Procedure					0.294
Center (Study Site)					<0.001

©: Kaplan-Meier estimate of incidence rate (This may be different from the crude rate).
 A, B, C — Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.
 All p-values from the pairwise comparisons are provided in Table 31 of the CSR.



MK-0966 Protocol 066 - Phase III Dental Pain #1
 Analysis of Pain Relief Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Placebo	N†	50	50	50	41	21	14	13	13	10	10	6	5
	MEAN	0.9 A	0.7 B	0.7 B	0.7 B	0.7 B	0.7 B	0.8 B	0.6 B	0.6 B	0.4 C	0.3 B	0.2 B
	STD	0.8	0.9	0.9	1.1	1.2	1.3	1.4	1.2	1.2	1.1	0.9	0.8
MK-0966 50 mg	N†	50	50	50	45	36	33	30	28	27	26	25	23
	MEAN	1.1 A	1.4 A	1.5 A	1.6 A	1.8 A	1.9 A	1.8 A	1.8 A	1.7 A	1.7 A	1.5 A	1.3 A
	STD	0.9	1.0	1.3	1.4	1.6	1.7	1.7	1.7	1.8	1.8	1.7	1.6
Ibuprofen 400 mg	N†	51	51	51	45	35	32	31	29	23	21	18	11
	MEAN	0.9 A	1.1 A	1.3 A	1.4 A	1.7 A	1.7 A	1.7 A	1.5 A	1.3 A	1.1 B	0.8 B	0.5 B
	STD	0.9	0.9	1.1	1.2	1.6	1.6	1.6	1.7	1.7	1.6	1.3	1.1
Pooled SD		0.9	0.9	1.1	1.2	1.5	1.5	1.6	1.6	1.6	1.5	1.4	1.2
Effect		p-Values by Timepoint (Hours Postdose)											
Treatment††		0.494	<0.001	<0.001	<0.001	<0.001	<0.001	0.001	<0.001	0.002	<0.001	<0.001	<0.001
Stratum(Baseline PI) †††		0.548	0.575	0.697	0.965	0.310	0.361	0.638	0.896	0.733	0.530	0.302	0.931
Rx-by-Stratum Interaction†††		0.634	0.854	0.895	0.571	0.816	0.802	0.655	0.588	0.514	0.947	0.967	0.892
† — Observed sample size †† — Model included treatment, baseline Pain Intensity (PI) as factors. ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors. A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.													

MK-0966 Protocol 066 - Phase III Dental Pain #1
 Analysis of PID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward





Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward												
		0.5	1	1.5	2	3	4	5	6	7	8	12	24	
Placebo	N†	50	50	50	41	21	14	13	13	10	6	5		
	MEAN	0.2 A	-0.1 B	-0.3 B	-0.1 B	0.3 B	0.3 B	0.3 B	0.2 B	0.3 B	0.2 C	0.1 B	0.1 B	
	STD	0.8	0.8	0.8	0.8	0.6	0.5	0.6	0.6	0.6	0.6	0.5	0.4	0.4
MK-0966 50 mg	N†	50	50	50	45	36	33	30	28	27	26	25	23	
	MEAN	0.3 A	0.5 A	0.5 A	0.6 A	0.7 A	0.9 A	0.8 A	0.9 A	0.8 A	0.9 A	0.7 A	0.6 A	
	STD	0.7	0.7	0.9	0.9	0.8	0.8	0.9	0.9	0.9	0.9	0.8	0.8	
Ibuprofen 400 mg	N†	51	51	51	45	35	32	31	29	23	21	18	11	
	MEAN	0.3 A	0.3 A	0.4 A	0.5 A	0.8 A	0.8 A	0.8 A	0.6 A	0.7 A	0.6 B	0.3 B	0.2 B	
	STD	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9	0.7	0.5	
Pooled SD		0.7	0.8	0.8	0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.7	0.6	
Effect		p-Values by Timepoint (Hours Postdose)												
Treatment††		0.862	<0.001	<0.001	<0.001	<0.001	<0.001	0.002	<0.001	0.002	<0.001	<0.001	<0.001	
Stratum(Baseline PI) †††		0.045	0.023	0.012	0.009	0.451	0.390	0.181	0.056	0.047	0.631	0.988	0.556	
Rx-by-Stratum Interaction†††		0.938	0.857	0.838	0.994	0.332	0.346	0.191	0.145	0.113	0.591	0.931	0.713	

† — Observed sample size
 †† — Model included treatment, baseline Pain Intensity (PI) as factors.
 ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.


MK-0966 Protocol 066 - Phase III Dental Pain #1
 Analysis of PRID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Placebo	N†	50	50	50	41	21	14	13	13	10	10	6	5
	MEAN	1.1 A	0.6 B	0.4 B	0.6 B	0.9 B	1.0 B	1.1 B	0.8 B	0.8 B	0.6 C	0.4 B	0.3 B
	STD	1.5	1.6	1.7	1.8	1.7	1.8	1.9	1.8	1.8	1.8	1.5	1.2
MK-0966 50 mg	N†	50	50	50	45	36	33	30	28	27	26	25	23
	MEAN	1.4 A	1.9 A	2.0 A	2.2 A	2.5 A	2.8 A	2.7 A	2.6 A	2.5 A	2.6 A	2.2 A	1.9 A
	STD	1.5	1.5	2.1	2.3	2.3	2.5	2.5	2.6	2.6	2.7	2.5	2.3
Ibuprofen 400 mg	N†	51	51	51	45	35	32	31	29	23	21	18	11
	MEAN	1.1 A	1.4 A	1.7 A	1.9 A	2.5 A	2.6 A	2.5 A	2.1 A	2.0 A	1.7 B	1.1 B	0.7 B
	STD	1.5	1.7	1.8	1.9	2.4	2.4	2.5	2.6	2.5	2.5	1.9	1.6
Pooled SD		1.5	1.6	1.9	2.0	2.2	2.3	2.3	2.4	2.3	2.3	2.0	1.8
Effect		p-Values by Timepoint (Hours Postdose)											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Treatment††		0.638	<0.001	<0.001	<0.001	<0.001	<0.001	0.001	<0.001	0.002	<0.001	<0.001	<0.001
Stratum(Baseline PI) †††		0.534	0.424	0.354	0.302	0.677	0.738	0.883	0.449	0.365	0.799	0.482	0.898
Rx-by-Stratum Interaction†††		0.769	0.841	0.861	0.784	0.637	0.661	0.458	0.391	0.337	0.877	0.988	0.841
† — Observed sample size †† — Model included treatment, baseline Pain Intensity (PI) as factors. ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors. A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.													

MK-0966 Protocol 071 - Phase III Dental Pain #2
 Analysis of Pain Relief Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Treatment Group



—●—●—●—●— Placebo
 -▲-▲-▲ MK-0966 100 mg
 -○-○-○ MK-0966 50 mg
 -□-□-□ MK-0966 200 mg

Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Placebo	N†	50	50	50	24	12	5	4	4	4	4	2	1
	MEAN	0.7 AB	0.9 C	0.9 C	0.6 C	0.3 C	0.2 C	0.3 C	0.3 D	0.2 D	0.2 C	0.1 C	0.1 C
	STD	0.9	0.9	0.9	0.9	0.7	0.8	1.0	1.0	0.8	0.7	0.4	0.4
MK-0966 50 mg	N†	50	50	50	38	34	32	30	28	26	25	23	20
	MEAN	0.6 AB	1.3 B	1.6 B	1.9 B	2.0 B	2.0 B	1.9 B	1.8 B	1.8 B	1.6 B	1.4 B	1.3 B
	STD	0.8	1.1	1.3	1.3	1.6	1.7	1.7	1.8	1.8	1.8	1.7	1.7
MK-0966 100 mg	N†	51	51	52	46	45	45	44	44	39	38	36	31
	MEAN	0.6 B	1.3 AB	1.9 AB	2.3 AB	2.7 A	2.8 A	2.7 A	2.5 A	2.4 A	2.3 A	2.0 A	2.0 A
	STD	0.7	0.9	1.0	1.2	1.3	1.3	1.3	1.4	1.6	1.6	1.7	1.8
MK-0966 200 mg	N†	50	50	50	44	42	39	38	38	37	36	34	31
	MEAN	0.9 A	1.7 A	2.3 A	2.5 A	2.6 A	2.7 A	2.7 A	2.6 A	2.6 A	2.5 A	2.2 A	2.1 A
	STD	0.9	1.2	1.3	1.5	1.5	1.6	1.6	1.7	1.7	1.7	1.8	1.8
Ibuprofen 400 mg	N†	52	52	52	42	38	33	27	21	19	15	6	4
	MEAN	0.9 AB	1.6 AB	1.9 AB	2.0 AB	2.0 B	1.7 B	1.4 B	1.1 C	0.9 C	0.5 C	0.3 C	0.2 C
	STD	1.0	1.2	1.3	1.4	1.6	1.6	1.6	1.5	1.4	1.1	0.9	0.9
Pooled SD		0.9	1.1	1.2	1.3	1.4	1.4	1.5	1.5	1.5	1.4	1.4	1.4
Effect		p-Values by Timepoint (Hours Postdose)											
		0.133	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Treatment††		0.052	0.021	0.005	0.120	0.281	0.588	0.623	0.500	0.642	0.937	0.718	0.573
Rx-by-Straum Interaction†††		0.800	0.436	0.713	0.717	0.772	0.610	0.660	0.625	0.476	0.192	0.223	0.482

† — Observed sample size
 †† — Model included treatment, baseline Pain Intensity (PI) as factors.
 ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 071 - Phase III Dental Pain #2
 Analysis of PID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward





Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Placebo	N†	50	50	50	24	12	5	4	4	4	4	2	1
	MEAN	0.2 AB	0.2 C	0.2 C	0.3 C	0.1 C	0.1 C	0.1 C	0.1 D	0.1 D	0.1 C	0.0 C	0.0 C
	STD	0.7	0.9	0.8	0.5	0.4	0.4	0.5	0.5	0.4	0.3	0.1	0.1
MK-0966 50 mg	N†	50	50	50	38	34	32	30	28	26	25	23	20
	MEAN	0.1 B	0.5 B	0.7 B	1.0 B	1.1 B	1.1 B	1.1 B	1.0 B	1.0 B	0.9 B	0.8 B	0.8 B
	STD	0.7	1.0	1.0	0.9	1.0	1.1	1.1	1.1	1.1	1.2	1.1	1.1
MK-0966 100 mg	N†	51	51	52	46	45	45	44	44	39	38	36	31
	MEAN	0.1 B	0.6 AB	0.9 B	1.2 AB	1.5 A	1.6 A	1.5 A	1.4 AB	1.3 AB	1.3 AB	1.1 AB	1.1 AB
	STD	0.6	0.7	0.8	0.8	0.9	0.9	0.9	1.0	1.0	1.0	1.1	1.1
MK-0966 200 mg	N†	50	50	50	44	42	39	38	38	37	36	34	31
	MEAN	0.4 A	0.9 A	1.3 A	1.5 A	1.5 A	1.5 A	1.5 A	1.5 A	1.5 A	1.4 A	1.3 A	1.2 A
	STD	0.6	0.8	0.9	1.0	1.0	1.0	1.1	1.1	1.1	1.1	1.1	1.1
Ibuprofen 400 mg	N†	52	52	52	42	38	33	27	21	19	15	6	4
	MEAN	0.3 AB	0.7 AB	0.9 B	1.1 B	1.2 B	0.9 B	0.7 B	0.6 C	0.5 C	0.3 C	0.2 C	0.2 C
	STD	0.8	1.0	1.0	0.9	1.0	1.0	1.0	0.9	0.9	0.8	0.6	0.6
Pooled SD		0.6	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9	0.9	0.9
Effect		p-Values by Timepoint (Hours Postdose)											
		0.5	1	1.5	2	3	4	5	6	7	8	12	24
Treatment††		0.011	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Stratum(Baseline PI) †††		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	0.003	0.015
Rx-by-Stratum Interaction†††		0.759	0.192	0.901	0.086	0.036	0.014	0.028	0.042	0.103	0.229	0.090	0.262

† — Observed sample size
 †† — Model included treatment, baseline Pain Intensity (PI) as factors.
 ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 071 - Phase III Dental Pain #2
 Analysis of PRID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward




Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8, 12, and 24 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose) - Baseline Observation Carried Forward												
		0.5	1	1.5	2	3	4	5	6	7	8	12	24	
Placebo	N†	50	50	50	24	12	5	4	4	4	4	2	1	
	MEAN	0.9ABC	1.1C	1.0C	0.9C	0.4C	0.3C	0.4C	0.4D	0.3D	0.3C	0.1C	0.1C	
	STD	1.5	1.7	1.7	1.3	1.1	1.2	1.5	1.5	1.2	1.1	0.6	0.6	
MK-0966 50 mg	N†	50	50	50	38	34	32	30	28	26	25	23	20	
	MEAN	0.7 BC	1.8 B	2.3 B	2.9 B	3.1 B	3.1 B	3.0 B	2.9 B	2.8 B	2.6 B	2.2 B	2.0 B	
	STD	1.4	2.0	2.3	2.2	2.5	2.8	2.8	2.8	2.9	2.8	2.8	2.8	
MK-0966 100 mg	N†	51	51	52	46	45	45	44	44	39	38	36	31	
	MEAN	0.7 C	2.0 B	2.8 B	3.5 AB	4.2 A	4.3 A	4.1 A	3.9 A	3.8 A	3.6 A	3.1 AB	3.1 A	
	STD	1.2	1.6	1.7	1.9	2.1	2.2	2.2	2.3	2.5	2.6	2.7	2.8	
MK-0966 200 mg	N†	50	50	50	44	42	39	38	38	37	36	34	31	
	MEAN	1.4 A	2.7 A	3.6 A	4.0 A	4.1 A	4.2 A	4.2 A	4.1 A	4.1 A	3.9 A	3.5 A	3.3 A	
	STD	1.5	1.9	2.2	2.4	2.4	2.5	2.6	2.7	2.7	2.7	2.9	2.9	
Ibuprofen 400 mg	N†	52	52	52	42	38	33	27	21	19	15	6	4	
	MEAN	1.2 AB	2.3 AB	2.8 B	3.1 B	3.2 B	2.6 B	2.1 B	1.7 C	1.5 C	0.8 C	0.5 C	0.4 C	
	STD	1.6	2.2	2.3	2.3	2.6	2.6	2.5	2.3	2.2	1.9	1.5	1.4	
Pooled SD		1.4	1.8	1.9	2.0	2.2	2.3	2.3	2.3	2.4	2.3	2.3	2.3	
Effect		p-Values by Timepoint (Hours Postdose)												
Treatment		0.041	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	
Stratum(Baseline PI)		<0.001	<0.001	<0.001	<0.001	0.001	0.011	0.019	0.017	0.034	0.142	0.349	0.558	
Rx-by-Stratum Interaction		0.784	0.303	0.810	0.408	0.401	0.263	0.334	0.369	0.381	0.296	0.259	0.555	

† — Observed sample size
 †† — Model included treatment, baseline Pain Intensity (PI) as factors.
 ††† — Model included treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model ††† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 055 - Phase III Dysmenorrhea #1
Analysis of Pain Relief Over Time (Intention-to-Treat) - Baseline Observation Carried Forward





Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose)											
		0.5	1	1.5	2	3	4	5	6	7	8	12	
Placebo	N†	60	60	59	58	50	47	46	41	38	38	31	
	MEAN	0.6 A	1.0 B	1.3 B	1.4 B	1.5 B	1.4 B	1.5 B	1.5 B	1.6 B	1.5 B	1.2 B	
	STD	0.9	1.1	1.1	1.4	1.4	1.3	1.5	1.5	1.6	1.7	1.6	
MK-0966 50/25 mg	N†	60	60	59	57	57	55	52	51	49	48	45	
	MEAN	0.7 A	1.4 A	1.6 B	2.0 A	2.5 A	2.6 A	2.6 A	2.6 A	2.5 A	2.4 A	2.3 A	
	STD	1.0	1.2	1.2	1.3	1.5	1.6	1.5	1.5	1.6	1.6	1.8	
Naproxen Sodium	N†	59	58	58	57	55	55	54	49	48	47	43	
	MEAN	0.8 A	1.6 A	2.2 A	2.5 A	2.8 A	2.9 A	2.7 A	2.7 A	2.6 A	2.5 A	2.2 A	
	STD	0.9	1.3	1.4	1.3	1.3	1.3	1.5	1.6	1.6	1.7	1.7	
Within Patient Pooled SD		0.8	1.1	1.2	1.3	1.4	1.3	1.4	1.4	1.5	1.5	1.4	
Effect		p-Values by Timepoint (Hours Postdose)											
		0.5	1	1.5	2	3	4	5	6	7	8	12	
Sequence††		0.947	0.515	0.596	0.628	0.622	0.360	0.586	0.721	0.760	0.722	0.664	
Patient(Sequence) ††		<0.001	0.053	0.078	0.087	0.247	0.148	0.019	0.029	0.013	0.036	<0.001	
Period(Square) ††		0.588	0.958	0.135	0.065	0.061	0.107	0.051	0.070	0.139	0.264	0.307	
Treatment††		0.405	0.003	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	
Stratum (Baseline PI) ††		0.739	0.869	0.253	0.321	0.979	0.729	0.979	0.897	0.889	0.777	0.543	
Carry-over (Residual) ††		0.134	<0.001	0.004	0.045	0.008	0.039	0.106	0.180	0.031	0.091	0.112	
Rx-by-Stratum Interaction†††		0.998	0.370	0.303	0.502	0.400	0.418	0.076	0.095	0.087	0.243	0.080	

†: Observed sample size
††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.
†††: Model included sequence, patient (sequence), period, treatment, baseline PI and treatment-by-baseline PI interaction as factors.
A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 055 - Phase III Dysmenorrhea #1
 Analysis of PID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward





Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	60	60	59	58	50	47	46	41	38	38	31
	MEAN	0.3 A	0.5 B	0.6 C	0.7 C	0.8 B	0.8 B	0.8 B	0.8 B	0.9 B	0.8 B	0.7 B
	STD	0.6	0.9	0.8	0.9	0.9	0.9	0.9	0.9	1.0	1.0	1.1
MK-0966 50/25 mg	N†	60	60	59	57	57	55	52	51	49	48	46
	MEAN	0.3 A	0.6 AB	0.9 B	1.1 B	1.4 A	1.5 A	1.5 A	1.6 A	1.5 A	1.4 A	1.4 A
	STD	0.6	0.8	0.8	0.8	1.0	1.1	1.0	1.0	1.1	1.1	1.1
Naproxen Sodium	N†	59	58	58	57	55	55	54	50	48	47	43
	MEAN	0.3 A	0.8 A	1.2 A	1.4 A	1.6 A	1.6 A	1.5 A	1.5 A	1.5 A	1.3 A	1.2 A
	STD	0.5	0.8	0.9	0.9	0.8	0.9	1.0	1.0	1.1	1.1	1.1
Within Patient Pooled SD		0.5	0.7	0.7	0.8	0.8	0.9	0.8	0.8	0.9	0.9	0.9
Effect		p-Values by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Sequence††		0.969	0.956	0.918	0.905	0.707	0.559	0.711	0.680	0.718	0.631	0.755
Patient(Sequence) ††		<0.001	<0.001	0.003	0.041	0.047	0.025	0.010	<0.001	<0.001	0.001	<0.001
Period(Square) ††		0.405	0.730	0.513	0.087	0.270	0.166	0.077	0.112	0.265	0.454	0.667
Treatment††		0.849	0.013	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Stratum (Baseline PI) ††		0.005	0.027	0.050	0.063	0.012	<0.001	0.002	0.008	0.001	0.009	0.009
Carry-over (Residual) ††		0.008	<0.001	0.004	0.027	0.007	0.082	0.104	0.096	0.088	0.075	0.081
Rx-by-Stratum Interaction†††		0.738	0.426	0.354	0.094	0.291	0.022	0.019	0.037	0.018	0.062	0.073

†: Observed sample size
 ††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.
 †††: Model included sequence, patient (sequence), period, treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 055 - Phase III Dysmenorrhea #1
 Analysis of PRID Over Time (Intention-to-Treat) - Baseline Observation Carried Forward





Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	60	60	59	58	50	47	46	41	38	38	31
	MEAN	0.9 A	1.4 B	1.8 B	2.1 C	2.3 B	2.2 B	2.3 B	2.3 B	2.4 B	2.3 B	1.8 B
	STD	1.4	1.9	1.8	2.2	2.2	2.2	2.3	2.4	2.6	2.6	2.6
MK-0966 50/25 mg	N†	60	60	59	57	57	55	52	51	49	48	45
	MEAN	1.0 A	2.0 AB	2.5 B	3.1 B	4.0 A	4.0 A	4.1 A	4.2 A	4.0 A	3.8 A	3.6 A
	STD	1.5	2.0	1.9	2.0	2.5	2.5	2.5	2.4	2.6	2.6	2.8
Naproxen Sodium	N†	59	58	58	57	55	55	54	49	48	47	43
	MEAN	1.1 A	2.5 A	3.3 A	3.9 A	4.3 A	4.5 A	4.3 A	4.2 A	4.1 A	3.8 A	3.4 A
	STD	1.3	2.0	2.1	2.1	2.0	2.0	2.3	2.4	2.6	2.7	2.8
Within Patient Pooled SD		1.1	1.8	1.8	2.0	2.1	2.1	2.2	2.2	2.3	2.4	2.2
Effect		p-Values by Timepoint (Hours Postdose)										
Sequence††		0.964	0.751	0.729	0.753	0.640	0.423	0.615	0.723	0.763	0.707	0.695
Patient(Sequence) ††		<0.001	0.010	0.034	0.072	0.218	0.122	0.025	0.013	0.007	0.017	<0.001
Period(Square) ††		0.465	0.970	0.250	0.069	0.143	0.162	0.058	0.078	0.174	0.315	0.435
Treatment††		0.742	0.003	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Stratum (Baseline PI) ††		0.321	0.437	0.959	0.894	0.323	0.109	0.213	0.356	0.171	0.408	0.528
Carry-over (Residual) ††		0.030	<0.001	0.002	0.030	0.006	0.044	0.095	0.136	0.042	0.078	0.099
Rx-by-Stratum Interaction†††		0.938	0.359	0.307	0.280	0.336	0.163	0.048	0.065	0.052	0.152	0.069

†: Observed sample size
 ††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.
 †††: Model included sequence, patient (sequence), period, treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model †† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.

MK-0966 Protocol 056 - Phase III Dysmenorrhea #2
 Analysis of Pain Relief Over Time (Intention-to-Treat) - Baseline Observation Carried Forward



Note: To enhance the visual clarity of the data between 0-8 hours, the distance between 8 and 12 hours on the x-axis is not to scale

Treatment		Summary Statistics by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Placebo	N†	118	118	118	117	99	89	83	78	72	67	64
	MEAN	0.3 A	0.8 C	1.4 B	1.7 B	1.8 B	1.8 B	1.7 B	1.6 B	1.6 B	1.6 B	1.5 B
	STD	0.6	1.1	1.4	1.5	1.6	1.6	1.7	1.8	1.7	1.8	1.8
MK-0966 25/25 mg	N†	115	115	113	113	107	99	97	94	90	89	84
	MEAN	0.4 A	0.9 BC	1.6 B	2.1 A	2.5 A	2.5 A	2.6 A	2.5 A	2.5 A	2.3 A	1.9 A
	STD	0.8	1.1	1.3	1.5	1.4	1.5	1.6	1.7	1.7	1.7	1.8
MK-0966 50/25 mg	N†	117	118	118	118	112	103	96	93	92	91	87
	MEAN	0.5 A	1.1 AB	1.6 B	2.2 A	2.4 A	2.5 A	2.6 A	2.7 A	2.5 A	2.3 A	2.2 A
	STD	0.8	1.2	1.3	1.5	1.5	1.6	1.6	1.6	1.7	1.7	1.7
Naproxen Sodium	N†	122	122	121	121	113	111	106	103	96	92	87
	MEAN	0.5 A	1.3 A	2.0 A	2.3 A	2.6 A	2.7 A	2.6 A	2.6 A	2.5 A	2.4 A	2.1 A
	STD	0.9	1.2	1.4	1.4	1.5	1.5	1.6	1.7	1.7	1.7	1.8
Within Patient Pooled SD		0.7	1.0	1.1	1.3	1.3	1.3	1.4	1.4	1.4	1.4	1.4
Effect		p-Values by Timepoint (Hours Postdose)										
		0.5	1	1.5	2	3	4	5	6	7	8	12
Sequence††		0.207	0.687	0.717	0.606	0.605	0.785	0.870	0.809	0.502	0.554	0.344
Patient(Sequence) †††		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Period(Square) ††		0.124	0.166	0.077	0.034	0.027	0.315	0.327	0.228	0.102	0.082	0.112
Treatment††		0.273	0.004	0.007	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
Stratum (Baseline PI) ††		0.373	0.263	0.043	0.122	0.069	0.130	0.201	0.255	0.429	0.183	0.619
Carry-over (Residual) ††		0.668	0.292	0.375	0.163	0.509	0.291	0.256	0.191	0.134	0.377	0.696
Rx-by-Stratum Interaction†††		0.715	0.811	0.785	0.959	0.824	0.343	0.476	0.460	0.162	0.380	0.924

†: Observed sample size
 ††: Model included sequence, patient (sequence), period, treatment, baseline Pain Intensity (PI) as factors.
 †††: Model included sequence, patient (sequence), period, treatment, baseline PI and treatment-by-baseline PI interaction as factors.
 A, B, C — Based on Model ††† LSMeans. Letter A indicates the most effective dose(s), B indicates the next most effective, and so forth. Treatments sharing at least one letter were not significantly different from each other at the 5% significance level.